Koek, W., Patoiseau, J.F., Assie, M.B., Cosi, C. and Kleven, M.S. Dupont-Passelaigue, E., Carilla-Durand, E., Palmier, C., Valentin, J.P., John, G., Pauwels, P. J., Tarayre, J.-P. and Colpaert, F.C. (1998) F 11440, a Potent, Selective, High Efficacy 5-HT1A Receptor Agonist with Marked Anxiolytic and Anti-Depressant Potential. Journal of Pharmacology and Experimental Therapeutics, 287, 266-283.

has been cited by the following article:

• TITLE: Synthesis of Fluorinated Heterobicyclic Nitrogen Systems Containing 1,2,4-Triazine Moiety as CDK2 Inhibition Agents

  AUTHORS: Mohammed Saleh Tawfik Makki, Reda Mohammdy Abdel-Rahman, Faisal Mohammed Aqlan

  KEYWORDS: Synthesis, Fluoroheterobicyclic Nitrogen, CDK2 Inhibition, Anti-Tumor Activity

  JOURNAL NAME: International Journal of Organic Chemistry, Vol.5 No.3, September 28, 2015

  ABSTRACT: New fluorine substituted heterobicyclic nitrogen system as imidozolopyrimidines (2,3), pyrimido- 1,2,4-triazinones (4-7), 1,2,4-triazinyl-1,2,4-triazine (12-16), 1,2,4-triazinyl-1,2,4-triazinones (14-17) and substituted thiobarbituric acids (19-20), have been synthesized using the reaction of 3- amino-5,6-di (4'-fluorophenyl)-1,2,4-triazine (1) with α,β–bifunctional compounds. Structures of the title compounds were characterized by UV, IR, 1H/13C-NMR and mass spectrometric method. The studied compounds were tested for CDK2 inhibiting activity in DNA damage, as well as in vitro anti-tumor activity.